Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $13 to $10.
October 24, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Pacific Biosciences and lowered the price target from $13 to $10.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Pacific Biosciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100